September 28, 2017

The 53^rd ECCO Educational Workshop was held in Bucharest, Romania on September 28, 2017.  The faculty comprised Giovanni Maconi (Italy) and Marc Ferrante (Belgium), as well as Liana Simona Gheorghe, Alexandru Lupu, Roxana Zaharie and Dan Ionut Gheonea from Romania.

September 15, 2017

The ECCO Workshop in Lithuania was organised in the quiet and beautiful city of Kaunas. Philip Hendy, from London, and Antonio López-Sanromán, from Madrid and an EduCom Officer, joined the local faculty (Limas Kupcinkas, Gediminas Giudelis and Laimas Jonaitis). 

Arie Levine © ECCO

Fecal microbial transplantation (FMT) is an exciting and evolving methodology to transform the microbiota in microbiota-related diseases. The rationale behind FMT is "transfer of a healthy microbiota" from a donor to a patient with IBD, leading to a change in recipient microbiota towards that of a healthy donor. However, current methods are simplistic. Random healthy donors do not necessarily have an appropriate microbiota, and transferred microbiota may not colonise the recipient’s gut. Diet can rapidly degrade certain taxa or increase others, such that if the recipient diet is not appropriate, donor microbiota expansion may not occur or functionality may be impaired.

Salome de Pinho © ECCO

Aims of the research

The current therapeutic strategies for Inflammatory Bowel Disease (IBD) are limited by effectiveness and/or toxicity, and the selection of patients for therapy remains a major challenge. These clinical concerns highlight the unmet need to identify key mechanisms (molecular markers) capable of being selectively targeted with new and optimised therapies. Glycosylation is a major post-translational mechanism characterised by the addition of carbohydrate structures (glycans) to essentially all cells [1]. Evidence in other immune-mediated disorders has shown that protein N-glycosylation, particularly branched N-glycans, regulates T cell immune response and controls the threshold of T cell activation [2].

Bram Verstockt © ECCO

Aims of the research

The introduction of new non-anti-TNF agents such as the anti-adhesion and anti-IL-12/IL-23 molecules will increase the therapeutic armamentarium for patients with IBD. It is nevertheless anticipated that clinical response and adverse events will vary significantly between individuals. Therefore, we need predictors of efficacy and safety so that we can select the right drug at the right time for the right patient. Targeted strategies in patients with poor prognostic factors and head-to-head trials are currently lacking.

Edouard Louis © ECCO

The BIOCYCLE project has now been ongoing for almost 2.5 years. This project, funded by the European Commission under the Horizon 2020 programme, aims at exploring different aspects of the question of treatment de-escalation in moderate-severe Crohn’s Disease, first requiring a combination therapy with anti-TNF and antimetabolites to control the disease. Once the disease has been stabilised, an unsolved question is to whether it is possible to de-escalate therapy. This question is important for several reasons including safety, tolerance, quality of life or costs to name the most prominent. 

Dear friends and colleagues,

UR-CARE is online NOW!

This international database offered to you by ECCO’s research unit (IBDIM) has been designed for your patient records and your research studies.

Laurent Peyrin-Biroulet © ECCO

I am happy to inform all ECCO members that the Governing Board started working while everybody was still on the plane! This year, we arrived on Friday afternoon and could already discuss numerous points. First, it was decided to continue increasing the amount of money for grants to foster exchange across ECCO centres and support innovative scientific projects. 

The 13^th Congress of ECCO in Vienna is coming closer and so is the late registration deadline. Benefit from the late registration fee by registering up until January 31, 2018 (after this date the onsite registration fees will apply).

Julián Panés  ©  ECCO

Dear ECCO friends,

We are witnessing an exciting period in the development of new therapies for Inflammatory Bowel Diseases. New therapeutic targets, and new classes of drugs, are being integrated into our therapeutic armamentarium. However, when we consider the proportion of patients who respond to induction therapy and, among those, the fraction who achieve remission during maintenance, the percentage of initially treated patients in whom the disease is satisfactorily controlled over one year does not exceed 15%–30%.